Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Maze Therapeutics, Inc.NASDAQ: MAZE

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 13.6% from a year ago

Common stock stood at $50K at the end of Q1 FY2026, up 13.6% from a year earlier and up 2.0% from the prior quarter. Over 3 fiscal years it compounded at +32.6% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +13.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$50K+2.0% QoQ
Last fiscal yearDec 2025
$49K+2350.0% YoY
Year agoMar 2025
$44K+13.6% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.6%——
1 year+2350.0%——
3-year CAGR+32.6%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
49K USD
Year-over-year change
+2350.0%
3-year CAGR
+32.6%

Common Stock vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +13.6% is the 2nd highest of 6, against a peer median of +4.4%.
  • Common stock amounts to 0.0% of total assets for MAZE, versus a peer median of 0.0%.
MAZE Competitors
Common Stock for MAZE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IVAInventiva S.A.Dec 2025€1.93M EUR+101.8%+66.2%0.8%
PTCTPTC Therapeutics, Inc.Jun 2026$82K USD+5.1%+3.6%0.0%
MAZEMaze Therapeutics, Inc.Mar 2026$50K USD+13.6%+32.6%0.0%
SEPNSepterna, Inc.Sep 2026$47K USD+4.4%+146.6%0.0%
ARDXArdelyx, Inc.Mar 2026$25K USD+4.2%+6.3%0.0%
TVTXTravere Therapeutics, Inc.Sep 2026$9K USD+0.0%+14.5%0.0%
DMACDiaMedica Therapeutics Inc.Mar 2026$0 USD——0.0%
BIOABioAge Labs, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding MAZE) —+4.4%+14.5%0.0%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents99.92M29.16M196.81M189.25M
Short-term Investments000152.67M
Net Receivables0000
Inventory0000
Other Current Assets6.23M4.95M4.86M7.8M
Total Current Assets106.15M34.11M201.67M349.72M
Property, Plant & Equipment (Net)41.23M34.98M29.92M25.16M
Goodwill0000
Intangible Assets0000
Long-term Investments1.21M1.09M1.09M18.11M
Tax Assets0000
Other Non-current Assets1.37M1.32M7.87M4.14M
Total Non-current Assets43.81M37.39M38.87M47.41M
Total Assets149.96M71.5M240.54M397.13M
Account Payables1.59M2.02M1.94M1.79M
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities7.49M2.93M6.02M10.85M
Total Current Liabilities20.78M16.32M20.67M22.56M
Long-term Debt020.08M00
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities01969K1.09M
Total Non-current Liabilities27.73M45.13M22.97M19.61M
Total Liabilities48.51M61.45M43.64M42.16M
Common Stock21K22K2K49K
Retained Earnings(295.27M)(395.69M)(358.43M)(489.55M)
Accumulated OCI000110K
Other Stockholders Equity0000
Minority Interest0000
Total Equity101.44M10.05M196.9M354.97M
Total Debt32.06M49.62M26.63M23.31M
Net Debt(67.86M)20.47M(170.18M)(165.94M)

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.